First cell therapy company lists on the Oslo Stock Exchange
Zelluna, a developer of allogeneic ‘off the shelf’ T cell receptor based natural killer (TCR-NK) cells for the treatment of cancer, has announced the successful completion of a Business Combination and Private Placement on the Oslo Stock Exchange. The share capital increases relating to the issuance of… Read More